The protective effects of FK565against systemic infections with herpes simplex virus (HSV) and murine cytomegalovirus (MCMV), respiratory tract infection with influenza virus and zosteriform rash with HSVinvestigated in mice. FK565 showed excellent protective activities against showed potent protective effects at intravenous, subcutaneous and oral doses of 0.001 to 1 mg/kg. FK565markedly inhibited zosteriform spread of HSVon the flank skin at an intravenous dose of 0.1 mg/kg and the mice given FK565survived longer than the control mice. The peritoneal exudate cells from FK565-treated mice suppressed the growth of HSVin mouse embryo fibroblast more strongly than those from the control mice, although FK565 had no direct antiviral activity against HSV.These findings suggest that FK565enhanced the host defense ability against viral infections by nonspecific activiation of macrophages.
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Infections with herpes simplex virus (HSV) are ubiquitious in man and are usually locally restricted. However, they may cause generalized infections in immuno-incompetent newborns and in immunodeficient or immunosuppressedpatients1*. The most commondiseases are recurrent episodes of orallabial or genital disease that are localized on cutaneous or mucosal surfaces. HSVis a commoncause of fatal and sporadic encephalitis. HSVis also suspected to be an oncogenic agent, particularly in the development of cervical carcinoma2 5). Humancytomegalovirus (HCMV), one of the most cmmonviruses causing intrauterine infections in man, causes infections in about 0.4%~2.3% of all live births6). Transplacental infection of the fetuses results from either a primary maternal infection or the reactivation of a maternal infection during pregnancy. Most congenital infections rsulting from a reactivated maternal infection are asymptomatic7). However, after a primary maternal infection during pregnancy, 40%~50%of the fetuses are infected and 10%-15% of these fetuses develope an apparent disease8 '9) .
Several new nucleoside analogs have been developed which are potent inhibitors of herpes simplex virus (HSV) with low toxicity in v/v0lo'n). 9-(2-Hydroxyethoxymethyl)guanine (ACV) and i>5-(bromovinyl-2'-deoxyuridine) (BVDU) behave as analogs of thymidine and are selectively phosphorylated by the HSV-specified pyrimidine deoxynucleoside kinase (thymidine kinase, TK). Both drugs are then metabolized within the infected cells to their respective nucleoside triphosphates which then interfere with HSV-specified DNApolymerase and inhibit virus replication. Resistance to ACVhas been associated Wereported in previous papers that FK565, an immunoactive peptide was isolated from culture filtrates of Streptomyces olivaceogriseusi2~14) and the compoundinduced potent resistance against microbial, fungal and viral infections in normal and immunosuppressed mice15~18), in vivo tumoricidal activity19)20), inhibitory effect against murine tumor metastases21), and a broad spectrum of immunostimulatory activities such as adjuvant effects on humoral and cellular immunity and mitogenesis22).
In this study, we investigated the protective effect of FK565using animal infection models with HSV, murine cytomegalovirus (MCMV)and influenza virus. Male ICR strain mice aged 4 weeks in groups of 20 or 3 weeks in groups of 10 were used; male Balb/c nu/nu strain mice aged 6 weeks in groups of 7 were used. The animals were obtained from Japan SLC, Inc. and housed in an isolation room at 21~25°C upon reciept at our institution and supplied with food and water ad libitum.
Virus
Herpes simplex virus (HSV) type 1 (strains Miyama and Fukuda, acyclovir-sensitive) and type 2 (strain CL706, acyclovir resistant), murine cytomegalovirus (MCMV, salivary gland homogenates from mice infected with MCMV) and influenza virus (strain A/PR8) were used in these experiments. These viruses were stored at -70°C until used.
Experimental Infection Systemic Infection: HSVstrains Miyama and CL705were used to induce encephalitis in ICR strain mice aged 4 weeks in groups of 20. Mice were challenged intraperitoneally with 2.8 x 103pfu/mouse (0.2ml/mouse) of strain Miyama and with 1.6x 104pfu/mouse (0.2ml/mouse) of strain CL705. The surival rate of the infected animals was observed for 14 days after challenge. ICR strain mice aged 3 weeks in groups of 10 were challenged intraperitoneally with 0.2ml/mouse (2.9 x 105pfu/mouse) of MCMV. The survival rate of animals was observed for 10 days after challenge.
Respiratory Tract Infection: Influenza virus strain A/PR8was used to induce respiratory tract infection. 25 fi\ of viral suspension was intranasally inoculated to ICR strain mice aged 4 weeks in groups of 20, under pentobarbital anesthesia. The survival rate of animals was observed for 14 days after challenge and the lung consolidations were observed on days 4, 7 and 10 after challenge. The lung consolidations were graded according to the severity as follows: Grade 0; negative, 1; 10-20%, 2; 20-40%, 3; 40-60%, 4; 60-80% and 5; 80-100% or death.
Skin Infection: HSVstrain Fukuda was used to induce zosteriform rash on the flank in athymic nude mice, Balb/c nu/nu. Mice were intradermally challenged at an abdominal site with 3.7 x 107pfu/ mouse (50 /il/mouse). Zosteriform spread of skin lesion was observed after challenge of virus for 10 days. This model is particularly useful for estimation of viral spread along neurons because the zosteriform rash is an epiphenomenon that accompanies infection along the peripheral nervous system. The skin FEB. 1992 lesions were graded according to the severity as follows: Grade 0; negative, 1~3; vesicle, 4~6; moderate (zosteriform spread), 7~9; severe (zosteriform rash) and 10; death.
Dosing Schedule
In systemic infection with HSVor respiratory tract infection with influenza virus, FK565 at doses of 0.001 to 1 mg/kg was given intravenously, subcutaneously or orally 4 hours after challenge and thereafter once a day for 4 consecutive days (total 5 times). In systemic infection with MCMV, FK565 at doses of 0.001 to 1 mg/kg was given subcutaneously one day before challenge and one and 3 days after challenge (total 3 times). ACVat doses of 5, 10 and 15 mg/kg was given subcutaneously twice a day for 4 consecutive days after challenge (total 8 times). These doses of ACVwere those used clinically. In skin lesions with HSV, FK565 was given intravenously 4 hours after challenge and thereafter once a day for 4 consecutive days (total 5 times).
Plaque Assay In Vitro Antiviral Activity: Monolayers of embryonic fibroblast from ICR mice were cultured in Eagle's minimum essential medium (MEM) containing 10% fetal bovine serum (FBS) in a 24 wellmultiwell tray at 37°C in 5% CO2. 20pfu of HSVstrain Miyamawere adsorbed to the cells for 1 hour at 37°C in 5% CO2. The cells were washed with 5% FBS-MEM and thereafter cultured in 5%
FBS-MEMcontaining 1.0 to 100//g/ml of FK565 and 0.5% human immunoglobulin for 3 days at 37°C in 5% CO2. The infected cells fixed with 5% trichloroacetic acid were stained with 0.1% crystal violet and the plaques were counted by microscopy. The meanvalues were obtained from 4 preparations.
Ex Vivo Antiviral Activity: FK565 of 0.001 to 1mg/kg was given intravenously once a day for 3 consecutive days in groups of 8 ICR strain mice and the peritoneal exudate cells (PEC) were collected from the peritoneal cavity and were pooled in each dose on the next day of final dosing. Monolayers of embryonic fibroblasts (2 x 105cells/well) from ICR mice were infected with HSV strain Miyama at O.l pfu/cell and thereafter co-cultured with those PEC (2 x 106 cells/well) from FK565-treated mice for 20 hours at 37°C in 5% CO2. The infected cells were scraped, sonicated and the viral yields were titrated by the plaque method using Vero cells. The mean values ofHSVtiters were obtained from 3 preparations.
Results

Protective Effect of FK565 against Systemic Infection with HSVin Mice
The results from systemic infections with ACV-sensitive and -resistant strains, Miyamaand CL705 are shown in Table 1 . In the intravenous and subcutaneous dosing groups for strain Miyama, 55% to 70% of the infected animals given 0.1 and 1 mg/kg of FK565 survived, and the survival rates were su- perior to that of the control with significant differences (P<0.05). In the oral dosing groups, the survival rate at 1 mg/kg was 30%and superior to that of the control. In the intravenous and subcutaneous dosing groups for strain CL705, 60% to 80% of the infected animals given 0.1 and 1mg/kg survived, and the survival rates were superior to those of the control. In the oral dosing groups, the survival rate at 1 mg/kg was low and FK565 had no effect.
Protective Effect of FK565 against Systemic Infection with MCMV
The results are shown in Table 2 . The survival rates at doses of 0.01 and 0.1 mg/kg were superior to that of the control. However, FK565 had no effect at 0.001 mg/kg and lower survival rate at 1 mg/kg than that at 0.1 mg/kg or 0.01 mg/kg suggested toxicity of the drug. The potent protection was observed when FK565 was given both before and after MCMV challenge in mice, but not when FK565 was given only after challenge. When ACVwas given at 10 and 15mg/kg twice a day after challenge, the survival rates weresuperior to that of the control. FK565 was given 0.001 to 1 mg/kg subcutaneously once a day 1 day before challenge and 1 and 3 days after challenge (total 3 times).
ACVwas given 5 to 15mg/kg subcutaneously twice a day 1, 2, 3 and 4 days after challenge (total 8 times).
Survival
rates were observed for 10 days after challenge.
Significant difference from the control (* P< 0.05) by Chi square test. Influenza virus was intranasally inoculated to ICR mice aged 4 weeks in groups of 20. FK565 was given 0.001 to 1 mg/kg intraperitoneally, subcutaneously and orally 4 hours after challenge and once a day for 4 days (total 5).
Survival rates were observed for 14 days after challenge. Significant difference from the control (* P<0.05, ** P<0.1) by Chi square test.
Protective Effect of FK565 against Respiratory Tract Infection with Influenza Virus
The results are shown in Table 3 and Fig. 1 . The animals were observed for 14 days after challenge. In the intravenous dose groups, the survival rates were 45 to 50% at doses of 0.001 to 1 mg/kg and were superior to that of the control. The survival rates were 45 to 50%in the subcutaneous dosing groups of 0.01 to 1mg/kg and 40 to 50% in the oral dosing groups of 0.1 to 1mg/kg. The protective effect by intravenous dosing was the most potent among subcutaneous and oral dosing. The inhibitory effects of FK565 on lung consolidations by influenza virus were dose-dependent when FK565 was given intravenously.
Inhibitory Effect of FK565 against Zosteriform Rash by HSV on Flank Skin The results are shown in Fig. 2 . Zosteriform spread of skin lesion with HSVin mice was inhibited markedly at 0.1 mg/kg of FK565 but not at 0.01 mg/kg. 85%of the untreated control mice died within 10 days after HSVchallenge. On day 10 after challenge, 60% of the animals given 0.1 mg/kg survived but all animals given 0.01 mg/kg died within 10 days.
Lack of Direct Antiviral Activity of FK565 FK565 in concentrations of 1.0 to 100/zg/ml did not decrease HSVplaque formation in a plaque assay method (Table 4 ). The results indicated that FK565 has no direct artiviral activity against HSV, even at a concentration of 100 /ig/ml.
Inhibitory Effect of Peritoneal Exudate Cells from FK565-treated Mice
Whenthe viral growth of HSVwas examined in the presence of peritoneal exudate cells (PEC) The mean values were obtained from 4 preparations. (Table 5 ). 58% to 72% inhibitory effects were observed at a dose of 0.001 to 1 mg/kg with significant difference from the control (P<0.05). The optimum dose was 0.1 mg/kg (72% inhibition).
Discussion
Our experiments demonstrated the striking protective effect of FK565in lethal encephalitis induced by two strains of HSV, one is ACV-sensitivity (ID50: strain Miyama; 0.38jUM) and one highly resistant to ACV(ID50: strain CL705; 36/zm). The protective effect of immunoactive peptide, FK565 against both ACV-sensitive and -resistant HSVinfection was dose-dependent. The effective doses of FK565were 0.1 to 1 mg/kg by the intravenous and subcutaneous routes and 1 mg/kg by oral route against the two strains. The potent inhibition of HSVinfection by FK565 was demonstrated by all routes: intravenous, subcutaneous and oral. In the mousesystemic infection with MCMV, FK565at doses of 0.01 and 0.1 mg/kg had potent protective action. This effect of FK565was superior to that of ACVat doses of 10 and 15 mg/kg. These results suggest that FK565may be useful in the treatment of primary maternal infection with HCMV during pregnancy. Against respiratory tract infection with influenza virus, the survival rates by FK565 ranged from 35% to 45% at doses of 0.01 to 1 mg/kg intravenously, subcutaneously or orally. The lung consolidations were mild in mice treated with FK565 at 0.1 or 1 mg/kg when compared with that in control mice.
FK565 showed inhibition on viral growth of HSVin the presence of peritoneal exudate cell previously activated by FK565 in vivo but could not inhibit that of HSVdirectly in vitro. These results suggest that FK565 possibly has no direct virucidal activity, but rather enhances the host defense ability, particularly macrophages against viral infection.
We reported that FK565 afforded resistance in normal or immunosuppressed mice against bacterial, fungal and friend leukemia virus infections by activating natural killer cells23), macrophages and the reticuloendothelial system24'25), and also by inducing colony stimulating factors26) or interleukin 1 production27'28).
Moreover some of these activities maintained for 5 to 7 days after a single dose.
Therefore, the inhibitory activity of FK565against viral infection appears to be due to activation of host defense mechanisms. FK565may have clinical potential if the mouse data can be applied to humans although toxicities in man are unknown.
